Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

The future of glycoprotein VI as an antithrombotic target.

Zahid M, Mangin P, Loyau S, Hechler B, Billiald P, Gachet C, Jandrot-Perrus M.

J Thromb Haemost. 2012 Dec;10(12):2418-27. doi: 10.1111/jth.12009. Review.

2.

New advances in treating thrombotic diseases: GPVI as a platelet drug target.

Jiang P, Jandrot-Perrus M.

Drug Discov Today. 2014 Sep;19(9):1471-5. doi: 10.1016/j.drudis.2014.06.005. Epub 2014 Jun 12. Review.

PMID:
24931218
3.

Platelet GPVI: a target for antithrombotic therapy?!

Dütting S, Bender M, Nieswandt B.

Trends Pharmacol Sci. 2012 Nov;33(11):583-90. doi: 10.1016/j.tips.2012.07.004. Epub 2012 Aug 15. Review.

PMID:
22901552
4.

[Advances of Studies on Platelet GPVI as Antithrombotic Target -Review].

Li P, Qiao JL, Xu KL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Feb;25(1):264-269. doi: 10.7534/j.issn.1009-2137.2017.01.048. Chinese.

PMID:
28245414
5.

Antiplatelet intervention in acute coronary syndrome.

Arora RR, Rai F.

Am J Ther. 2009 Sep-Oct;16(5):e29-40. doi: 10.1097/MJT.0b013e31804c7238. Review.

PMID:
19092648
6.

Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome.

Bigalke B, Geisler T, Stellos K, Langer H, Daub K, Kremmer E, Seizer P, May AE, Lindemann S, Gawaz M.

Am Heart J. 2008 Jul;156(1):193-200. doi: 10.1016/j.ahj.2008.02.010. Epub 2008 Apr 23.

PMID:
18585516
7.

Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients?

Campo G, Pavasini R, Pollina A, Fileti L, Marchesini J, Tebaldi M, Ferrari R.

Blood Coagul Fibrinolysis. 2012 Dec;23(8):680-7. doi: 10.1097/MBC.0b013e328355111f. Review.

PMID:
22688556
8.

Novel mechanistic concept of platelet inhibition.

Sigalov AB.

Expert Opin Ther Targets. 2008 Jun;12(6):677-92. doi: 10.1517/14728222.12.6.677 . Review.

PMID:
18479215
9.

Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.

Mousa SA, Bozarth JM, Forsythe MS, Jackson SM, Leamy A, Diemer MM, Kapil RP, Knabb RM, Mayo MC, Pierce SK, et al.

Circulation. 1994 Jan;89(1):3-12.

PMID:
8281661
10.

Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression.

Ohlmann P, Hechler B, Ravanat C, Loyau S, Herrenschmidt N, Wanert F, Jandrot-Perrus M, Gachet C.

J Thromb Haemost. 2008 Jun;6(6):1003-11. doi: 10.1111/j.1538-7836.2008.02976.x. Epub 2008 Apr 14.

11.

Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments.

Lecut C, Feeney LA, Kingsbury G, Hopkins J, Lanza F, Gachet C, Villeval JL, Jandrot-Perrus M.

J Thromb Haemost. 2003 Dec;1(12):2653-62.

12.

Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS).

Bigalke B, Stellos K, Weig HJ, Geisler T, Seizer P, Kremmer E, Pötz O, Joos T, May AE, Lindemann S, Gawaz M.

Basic Res Cardiol. 2009 May;104(3):352-7. doi: 10.1007/s00395-009-0779-7. Epub 2009 Feb 3.

PMID:
19190951
13.

Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy.

Grüner S, Prostredna M, Aktas B, Moers A, Schulte V, Krieg T, Offermanns S, Eckes B, Nieswandt B.

Circulation. 2004 Nov 2;110(18):2946-51. Epub 2004 Oct 25.

14.

A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents.

Mangin PH, Tang C, Bourdon C, Loyau S, Freund M, Hechler B, Gachet C, Jandrot-Perrus M.

J Pharmacol Exp Ther. 2012 Apr;341(1):156-63. doi: 10.1124/jpet.111.189050. Epub 2012 Jan 11.

15.

Genetics of platelet glycoprotein receptors: risk of thrombotic events and pharmacogenetic implications.

Mikkelsson J, Perola M, Karhunen PJ.

Clin Appl Thromb Hemost. 2005 Apr;11(2):113-25. Review.

PMID:
15821818
16.

Advances in antithrombotic therapy of acute myocardial infarction.

Gensini GF, Comeglio M, Falai M.

Am Heart J. 1999 Aug;138(2 Pt 2):S171-6. Review.

PMID:
10426878
17.

Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain.

Bigalke B, Haap M, Stellos K, Geisler T, Seizer P, Kremmer E, Overkamp D, Gawaz M.

Thromb Res. 2010 May;125(5):e184-9. doi: 10.1016/j.thromres.2010.01.005. Epub 2010 Feb 1.

PMID:
20122713
18.

Antiplatelet and antithrombin therapies in the acute coronary syndromes.

Alexander JH, Harrington RA.

Curr Opin Cardiol. 1997 Jul;12(4):427-37. Review.

PMID:
9263656
19.

Glycoprotein IIb/IIIa platelet receptor inhibitors: a new dimension in cardiology.

Tan HC.

Ann Acad Med Singapore. 1997 Jul;26(4):481-8. Review.

PMID:
9395815
20.

Platelet glycoprotein VI-related clinical defects.

Arthur JF, Dunkley S, Andrews RK.

Br J Haematol. 2007 Nov;139(3):363-72. Review.

PMID:
17910626

Supplemental Content

Support Center